Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-11-12FDA Approved: ZONEGRAN — Supplemental Application (Advanz Pharma (US) Corp.)
FDA approved a supplemental application for Zonegran (zonisamide) submitted by Advanz Pharma (US) Corp.
-
FDA approval · 2015-11-04FDA Approved: TIAGABINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Tiagabine Hydrochloride from Teva Pharmaceuticals USA, Inc., updating the drug's labeling as par…
-
FDA approval · 2015-11-04FDA Approved: FELBAMATE — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved the original application for a generic felbamate product from ANI Pharmaceuticals, Inc.
-
FDA approval · 2015-11-03FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for SABRIL (vigabatrin) from Lundbeck Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2015-11-03Clinical Trial Update: E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures [Phase 2]
A Phase 2 trial evaluated E2007 (perampanel) as adjunctive therapy for patients with refractory partial seizures. The study has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-11-03Clinical Trial Update: Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate [Phase 4]
A Phase 4 clinical trial compared cognitive outcomes of adjunctive zonisamide versus sodium valproate in epilepsy; the study has completed.
-
CLINICAL_TRIALS trial_result · 2015-11-02Clinical Trial Update: Levetiracetam to Prevent Post-Traumatic Epilepsy [Phase 2]
A Phase 2 trial evaluating levetiracetam to prevent post-traumatic epilepsy has completed, with results posted in 2015.
-
FDA approval · 2015-10-30FDA Approved: FLUDEOXYGLUCOSE F18 — Original Application (3D Imaging Drug Design and Development LLC)
FDA approved Fluorodeoxyglucose F18 (FDG F-18) as an original radiopharmaceutical for PET imaging to assess metabolic activity in oncology, …
-
FDA approval · 2015-10-30FDA Approved: TOPIRAMATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' supplemental application for Topiramate, updating the approved labeling for the product.
-
FDA approval · 2015-10-30FDA Approved: TOPIRAMATE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Topiramate submitted by Zydus Lifesciences Limited.
-
FDA approval · 2015-10-27FDA Approved: LAMOTRIGINE — Original Application (Endo USA, Inc.)
FDA approved Endo USA, Inc.'s generic lamotrigine under ANDA204158, allowing the generic product to be marketed for the same indications as …
-
FDA approval · 2015-10-26FDA Approved: ZONISAMIDE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for Zonisamide submitted by BluePoint Laboratories.
-
CLINICAL_TRIALS trial_result · 2015-10-23Clinical Trial Update: Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?
A completed clinical trial update examining whether valproate increases levels of folate receptor autoantibodies in women with epilepsy or p…
-
FDA approval · 2015-10-19FDA Approved: LEVETIRACETAM — Supplemental Application (Prinston Pharmaceutical Inc.)
FDA approved a supplemental application for levetiracetam from Prinston Pharmaceutical Inc. under ANDA078106.
-
CLINICAL_TRIALS research · 2015-10-16Clinical Trial Update: Epilepsy Birth Control Registry
Update on an epilepsy birth control registry clinical trial; the status is not specified.
-
FDA approval · 2015-10-15FDA Approved: FOSPHENYTOIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Fosphenytoin Sodium from Amneal Pharmaceuticals LLC, adding an updated approval for this generic…
-
FDA approval · 2015-10-12FDA Approved: TROKENDI XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for TROKENDI XR (topiramate) filed by Supernus Pharmaceuticals, Inc., indicating an expanded or upda…
-
CLINICAL_TRIALS research · 2015-10-09Clinical Trial Update: Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
Clinical trial update examining the impact of eslicarbazepine acetate on lipid metabolism and cardiovascular risk factors in epilepsy patien…
-
CLINICAL_TRIALS withdrawal · 2015-10-09Clinical Trial Update: Treatment Resistant Epilepsy and N-Acetyl Cysteine [NA]
A clinical trial investigating N-Acetyl Cysteine for treatment-resistant epilepsy in autism with irritability has been withdrawn; no results…
-
CLINICAL_TRIALS trial_result · 2015-10-05Clinical Trial Update: Bone Mineral Density in Pediatric Epilepsy
This is an update on a completed clinical trial evaluating bone mineral density in pediatric patients with epilepsy.
-
FDA approval · 2015-10-02FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's supplemental application for levetiracetam, a generic form of the antiepileptic drug, under up…
-
FDA approval · 2015-10-01FDA Tentative Approval: LAMOTRIGINE — Supplemental Application (NorthStar Rx LLC)
FDA tentatively approved NorthStar Rx LLC's generic lamotrigine product under an ANDA.
-
CLINICAL_TRIALS trial_result · 2015-10-01Clinical Trial Update: Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design [Phase 4]
Phase 4 study update assessing pharmacokinetic equivalence between generic and brand-name antiepileptic drugs in people with epilepsy using …
-
FDA approval · 2015-09-23FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote Sprinkles (divalproex sodium) from AbbVie, adding the sprinkle formulation to the produ…
-
FDA approval · 2015-09-23FDA Approved: DEPAKOTE — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote (divalproex sodium) submitted by AbbVie Inc.